Recombinant porcine factor VIII corrects thrombin generation in vitro in plasma from patients with congenital hemophilia A and inhibitors

BACKGROUND: Neutralizing factor VIII (FVIII) antibodies are a major complication in hemophilia A. Antihemophilic factor VIII (recombinant), porcine sequence (rpFVIII; susoctocog alfa; Baxalta US Inc., a Takeda company) has low cross‐reactivity to anti‐human FVIII antibodies and can provide functiona...

Descripción completa

Detalles Bibliográficos
Autores principales: Négrier, Claude, Oldenburg, Johannes, Kenet, Gili, Meeks, Shannon L., Bordet, Jean‐Claude, Müller, Jens, Le Quellec, Sandra, Turecek, Peter L., Tripkovic, Nikola, Dargaud, Yesim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9207117/
https://www.ncbi.nlm.nih.gov/pubmed/35765670
http://dx.doi.org/10.1002/rth2.12731

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9207117/
https://www.ncbi.nlm.nih.gov/pubmed/35765670
http://dx.doi.org/10.1002/rth2.12731

Ejemplares similares